These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35238866)

  • 21. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment options for HER2-expressing colorectal cancer: updates and recent approvals.
    Zheng-Lin B; Bekaii-Saab TS
    Ther Adv Med Oncol; 2024; 16():17588359231225037. PubMed ID: 38249334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
    Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Barry GS; Cheang MC; Chang HL; Kennecke HF
    Oncotarget; 2016 Apr; 7(14):18953-64. PubMed ID: 26980732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
    Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
    Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.
    Chen N; He L; Zou Q; Deng H
    Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
    Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
    Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
    Nagy P; Jenei A; Damjanovich S; Jovin TM; Szölôsi J
    Pathol Oncol Res; 1999; 5(4):255-71. PubMed ID: 10607920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
    Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
    Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.
    Zheng-Lin B; Graham RP; Bekaii-Saab TS
    Chin Clin Oncol; 2023 Oct; 12(5):55. PubMed ID: 37964543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
    Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
    Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
    Aoyama K; Kamio T; Nishikawa T; Kameoka S
    Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
    Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
    Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
    Vaghi C; Mauri G; Agostara AG; Patelli G; Pizzutilo EG; Nakamura Y; Yoshino T; Siena S; Sartore-Bianchi A
    Cancer Treat Rev; 2023 Jan; 112():102488. PubMed ID: 36410093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
    Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery.
    Lee JC; Wang ST; Chow NH; Yang HB
    Eur J Cancer; 2002 May; 38(8):1065-71. PubMed ID: 12008194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.